



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07D 401/04, A61K 31/44	A1	(11) International Publication Number: WO 93/14082 (43) International Publication Date: 22 July 1993 (22.07.93)
(21) International Application Number: PCT/US93/00675 (22) International Filing Date: 13 January 1993 (13.01.93) (30) Priority data: 07/819,552 13 January 1992 (13.01.92) US (60) Parent Application or Grant (63) Related by Continuation US 07/819,552 (CIP) Filed on 13 January 1992 (13.01.92) (71) Applicant (for all designated States except US): SMITH-KLINE BEECHAM CORPORATION [US/US]; One Franklin Plaza, P.O. Box 7929, Philadelphia, PA 19101 (US).	(72) Inventors; and (75) Inventors/Applicants (for US only) : ADAMS, Jerry, Leroy [US/US]; 611 Forest Road, Wayne, PA 19087 (US). GALLAGHER, Timothy, Francis [US/US]; 255 Manor Road, Harleysville, PA 19438 (US). GARIGIPATI, Ravi, Shanker [IN/US]; 5 Flintlock Lane, Wayne, PA 19087 (US). (74) Agents: DINNER, Dara, L. et al.; SmithKline Beecham Corporation, Corporate Patents - U.S., UW2220, 709 Swedeland Road, P.O. Box 1538, King of Prussia, PA 19406-0939 (US). (81) Designated States: AU, CA, JP, KR, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: PYRIDYL SUBSTITUTED IMIDAZOLES (57) Abstract The novel compounds of formula (I) have been found to be useful cytokine suppressive agents and therefore useful in the treatment and prophylaxis of disease states mediated thereby.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

5

PYRIDYL SUBSTITUTED IMIDAZOLES**1 0 FIELD OF THE INVENTION**

This invention relates to novel compounds and methods of treating interleukin-1 (IL-1), interleukin-8 (IL-8), and Tumor Necrosis Factor (TNF) mediated diseases.

1 5 BACKGROUND OF THE INVENTION

Interleukin-1 (IL-1) and Tumor Necrosis Factor (TNF) are biological substances produced by a variety of cells, such as monocytes or macrophages. IL-1 has been demonstrated to mediate a variety of biological activities thought to be important in immunoregulation and other physiological conditions such as inflammation [See, e.g., Dinarello et al., Rev. Infect. Disease, 6, 51 (1984)]. The myriad of known biological activities of IL-1 include the activation of T helper cells, induction of fever, stimulation of prostaglandin or collagenase production, neutrophil chemotaxis, induction of acute phase proteins and the suppression of plasma iron levels.

2 5 There are many disease states in which excessive or unregulated IL-1 production is implicated in exacerbating and/or causing the disease. These include rheumatoid arthritis, osteoarthritis, endotoxemia and/or toxic shock syndrome, other acute or chronic inflammatory disease states such as the inflammatory reaction induced by endotoxin or inflammatory bowel disease; tuberculosis, atherosclerosis, muscle degeneration, cachexia, psoriatic arthritis, Reiter's syndrome, rheumatoid
3 0 arthritis, gout, traumatic arthritis, rubella arthritis, and acute synovitis. Recent evidence also links IL-1 activity to diabetes and pancreatic β cells.

Dinarello, J. Clinical Immunology, 5 (5), 287-297 (1985), reviews the biological activities which have been attributed to IL-1. It should be noted that
3 5 some of these effects have been described by others as indirect effects of IL-1.

Excessive or unregulated TNF production has been implicated in mediating or exacerbating a number of diseases including rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions;

-2-

sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoisosis, bone resorption diseases, reperfusion injury, graft vs. host reaction, allograft rejections, fever and myalgias due to infection, such as influenza, cachexia secondary to infection or malignancy, cachexia, secondary to acquired immune deficiency syndrome (AIDS), AIDS, ARC (AIDS related complex), keloid formation, scar tissue formation, Crohn's disease, ulcerative colitis, or pyresis.

AIDS results from the infection of T lymphocytes with Human Immunodeficiency Virus (HIV). At least three types or strains of HIV have been identified, i.e., HIV-1, HIV-2 and HIV-3. As a consequence of HIV infection, T-cell mediated immunity is impaired and infected individuals manifest severe opportunistic infections and/or unusual neoplasms. HIV entry into the T lymphocyte requires T lymphocyte activation. Other viruses, such as HIV-1, HIV-2 infect T lymphocytes after T Cell activation and such virus protein expression and/or replication is mediated or maintained by such T cell activation. Once an activated T lymphocyte is infected with HIV, the T lymphocyte must continue to be maintained in an activated state to permit HIV gene expression and/or HIV replication. Monokines, specifically TNF, are implicated in activated T-cell mediated HIV protein expression and/or virus replication by playing a role in maintaining T lymphocyte activation. Therefore, interference with monokine activity such as by inhibition of monokine production, notably TNF, in an HIV-infected individual aids in limiting the maintenance of T cell activation, thereby reducing the progression of HIV infectivity to previously uninfected cells which results in a slowing or elimination of the progression of immune dysfunction caused by HIV infection. Monocytes, macrophages, and related cells, such as kupffer and glial cells, have also been implicated in maintenance of the HIV infection. These cells, like T-cells, are targets for viral replication and the level of viral replication is dependent upon the activation state of the cells. [See Rosenberg et al., The Immunopathogenesis of HIV Infection, Advances in Immunology, Vol. 57, (1989)]. Monokines, such as TNF, have been shown to activate HIV replication in monocytes and/or macrophages [See Poli, et al., Proc. Natl. Acad. Sci., 87:782-784 (1990)], therefore, inhibition of monokine production or activity aids in limiting HIV progression as stated above for T-cells.

TNF has also been implicated in various roles with other viral infections, such as the cytomegalia virus (CMV), influenza virus, and the herpes virus for similar reasons as those noted.

Interleukin -8 (IL-8) is a chemotactic factor first identified and characterized in 1987. IL-8 is produced by several cell types including mononuclear

cells, fibroblasts, endothelial cells, and ketainocytes. Its producti n from endothelidl
cells is induced by IL-1, TNF, or lipopolysachharide (LPS). Human IL-8 has been
shown to act n Mouse, Guinea Pig, Rat, and Rabbit Neutrophils. Many different
names have been applied to IL-8, such as neutophil attractant/activation protein-1
5 (NAP-1), monocyte derived neutrophil chemotactic factor (MDNCF), neutophil
activating factor (NAF), and T-cell lymphocyte chemotactic factor.

IL-8 stimulates a number of functions in vitro. It has been shown to
have chemoattractant properties for neutophils, T-lymphocutes, and basophils. In
addition it induces histamine release from basophils from both normal and atopic
1 0 individualss as well as lysozomal enzyme release and respiratory burst from
neutrophils. IL-8 has also been shown to increse the surface expression of Mac-1
(CD11b/CD18) on nuetophils without de novo protein synthesis, this may contribute
to increased adhesion of the neutrophils to vascular endothelial cells. Many diseases
are characterized by massive neutrophil infiltration. Conditions associated with an
1 5 increased in IL-8 production (which is responsible for chemotaxis of neutophils into
the inflammatory site) would benefit by compounds which are suppressive of IL-8
production.

IL-1 and TNF affect a wide variety of cells and tissues and these
cytokines as well as other leukocyte derived cytokines are important and critical
2 0 inflammatory mediators of a wide variety of disease states and conditions. The
inhibition of these cytokines is of benefit in controlling, reducing and alleviating
many of these disease states.

There remains a need for treatment, in this field, for compounds which
are cytokine suppressive anti-inflammatory drugs (hereinafter CSAID's), i.e.
2 5 compounds which are capable of inhibiting cytokines, such as IL-1, IL-6, IL-8 and
TNF.

SUMMARY OF THE INVENTION

This invention relates to the novel compounds of Formula (I) and
3 0 pharmaceutical compositions comprising a compound of Formula (I) and a
pharmaceutically acceptable diluent or carrier.

This invention also relates to a method of treating a cytokine mediated
disease, in a mammal in need thereof which comprises administering to said mammal
an effective amount of a compound of Formula (I).

3 5 This invention more specifically relates to a method of inhibiting the
production of IL-1 in a mammal in need thereof which comprises administering to
said mammal an effective amount of a compound of Formula (I).

This invention more specifically relates to a method of inhibiting the production of IL-8 in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I).

5 This invention more specifically relates to a method of inhibiting the production of TNF in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I).

This invention more specifically relates to a method of treating a human, afflicted with a human immunodeficiency virus (HIV), which comprises administering to said human an effective TNF inhibiting amount of a compound of
10 Formula (I).

The novel compounds of this invention are represented by the structure:



wherein

R₁ is a mono- or di- substituted 4-quinolyl, 4-pyridyl, 1-imidazolyl, 1-

benzimidazolyl, 4-pyrimidinyl wherein the substituent is independently selected from the group consisting of hydrogen, C₁₋₄ alkyl, halo,

20 O-C₁₋₄ alkyl, S-C₁₋₄ alkyl, or N(R_a)₂;

R_a is hydrogen, C₁₋₆alkyl, or R_a together with the nitrogen, may form a heterocyclic ring of 5 to 7 members, said ring optionally containing an additional heteroatom selected from the group consisting of oxygen, sulfur or nitrogen;

R₂ is mono- or di-substituted phenyl wherein the substituents are independently
25 selected from the group consisting of hydrogen, halo, S(O)_mR₅, OR₆, halo substituted C₁₋₄ alkyl, C₁₋₄ alkyl, or N(R₁₂)₂;

R₄ is hydrogen, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₃₋₇ cycloalkyl, C₅₋₇ cycloalkenyl, heterocyclic, heterocyclicalkyl, aryl, aryl alkyl, heteroaryl, heteroaryl alkyl ;

30 R₃ is (X)_r(Q)_s(Y)_t;

-5-

X is hydrogen, $-(C(R_{10})_2)_n$, $-NR_{13}$, $-O-$, or $S(O)_m$;

r is a number having a value of 0 or 1;

m is a number having a value of 0, 1 or 2;

Q is alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclic, heterocyclicalkyl, aryl,

5 arylalkyl, heteroaryl, or heteroarylalkyl;

s is a number having a value of 0 or 1;

Y is a substituent selected from the group consisting of hydrogen, C_{1-10} alkyl,

halo-substituted C_{1-10} alkyl, halogen, $-(C(R_{10})_2)_nOR_8$, $-(C(R_{10})_2)_nNO_2$,

$-(C(R_{10})_2)_nS(O)_mR_{11}$, $-(C(R_{10})_2)_nSR_8$, $-(C(R_{10})_2)_nS(O)_mOR_8$,

10 $-(C(R_{10})_2)_nS(O)_mNR_8R_9$, $-X_a-P(Z)-(X_aR_{13})_2$, $-(C(R_{10})_2)_nNR_8R_9$,

$-(C(R_{10})_2)_nCO_2R_8$, $-(C(R_{10})_2)_nOC(O)-R_8$, $-(C(R_{10})_2)_nCN$,

$-(C(R_{10})_2)_nCONR_8R_9$, $-(C(R_{10})_2)_nC(S)NR_8R_9$, $-(C(R_{10})_2)_nNR_{10}C(O)R_8$,

$-(C(R_{10})_2)_nNR_{10}C(S)R_8$, $-(C(R_{10})_2)_nNR_{10}C(Z)NR_8R_9$,

$-(C(R_{10})_2)_nNR_{10}S(O)_mR_{11}$, $-(C(R_{10})_2)_nNR_{10}C(=NCN)-S-R_{11}$,

15 $-(C(R_{10})_2)_nNR_{10}C(=NCN)-NR_8R_9$, $-(C(R_{10})_2)_nNR_{10}C(O)C(O)-NR_8R_9$,

$-(C(R_{10})_2)_nNR_{10}C(O)C(O)-OR_{10}$, $-(C(R_{10})_2)_nC(=NR_{10})-NR_8R_9$,

$-(C(R_{10})_2)_nC(=NR_{10})-ZR_{11}$, $-(C(R_{10})_2)_nOC(Z)-NR_8R_9$,

$-(C(R_{10})_2)_nNR_{10}S(O)_mCF_3$, $-(C(R_{10})_2)_nNR_{10}C(O)OR_{10}$;

t is an integer having a value of 0, 1, 2, or 3;

20 X_a is independently $-(C(R_{10})_2)_n$, $-NR_8$, $-O-$ or $-S-$;

Z is oxygen or sulfur;

m' is an integer having a value of 1 or 2;

n is an integer having a value of 0 to 10;

R_5 is hydrogen, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{3-7} cycloalkyl, C_{5-7}

25 cycloalkenyl, aryl, or $N(R_7)_2$; provided that when m is 1 or 2 then R_5 is not hydrogen.

R_6 is hydrogen, C_{1-4} alkyl, halo substituted C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl,

C_{3-7} cycloalkyl, C_{5-7} cycloalkenyl, or aryl;

-6-

- R₇ is hydrogen, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, aryl, or may form a heterocyclic ring of 5 to 7 members together with the nitrogen, said ring optionally containing an additional heteroatom selected from the group consisting of oxygen, sulfur or nitrogen; provided that when R₅ is N(R₇)₂ then m is 1 or 2;
- R₈ is hydrogen, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₃₋₇ cycloalkyl, C₅₋₇ cycloalkenyl, heterocyclic, heterocyclic alkyl, aryl, aryl alkyl, heteroaryl, heteroaryl alkyl ;
- R₉ is hydrogen, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₃₋₇ cycloalkyl, C₅₋₇ cycloalkenyl, aryl, aryl alkyl, heteroaryl, heteroaryl alkyl or R₈ and R₉ may together form a heterocyclic ring of 5 to 7 members together with the nitrogen, said ring optionally containing an additional heteroatom selected from the group consisting of oxygen, sulfur or nitrogen;
- R₁₀ is hydrogen, or C₁₋₄ alkyl;
- R₁₁ is C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₃₋₇ cycloalkyl, C₅₋₇ cycloalkenyl, aryl, aryl alkyl, heteroaryl, heteroaryl alkyl ;
- R₁₂ is hydrogen, C₁₋₄ alkyl, aryl, or may form a heterocyclic ring of 5 to 7 members together with the nitrogen;
- R₁₃ is hydrogen, C₁₋₁₀ alkyl, cycloalkyl, heterocyclic, aryl, aryl alkyl, heteroaryl, or heteroaryl alkyl;
- or a pharmaceutically acceptable salt thereof.

25 DETAILED DESCRIPTION OF THE INVENTION

This invention relates to a method of inhibiting the production of cytokines in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I).

- 30 The compounds of Formula (I) are useful in the treatment of viral infections, where such viruses are sensitive to upregulation by TNF or will elicit TNF

-7-

production in vivo. The viruses contemplated for treatment herein are those that produce TNF as a result of infection, or those which are sensitive to inhibition, such as by decreased replication, directly or indirectly, by the TNF inhibitors of Formula (1). Such viruses include, but are not limited to; HIV-1, HIV-2 and HIV-3,

5 Cytomegalovirus (CMV), Influenza, adenovirus and the Herpes group of viruses, such as but not limited to, Herpes Zoster and Herpes Simplex.

This invention more specifically relates to a method of treating a human, afflicted with a human immunodeficiency virus (HIV), which comprises


10 administering to such mammal an effective TNF inhibiting amount of a compound of Formula (I).

The compounds of Formula (I) may also be used in association with the veterinary treatment of animals, other than in humans, in need of inhibition of TNF

15 production. TNF mediated diseases for treatment, therapeutically or prophylactically, in animals include disease states such as those noted above, but in particular viral infections. Examples of such viruses include, but are not limited to, the lentivirus infections such as equine infectious anaemia virus, caprine arthritis virus, visna virus, or the maedi virus, or the retroviruses, such as feline immunodeficiency virus (FIV),

20 bovine immunodeficiency virus, or canine immunodeficiency virus.

For purposes herein of nomenclature the compounds of Formula (I) are named by their position corresponding to:



25

Preferred compounds of Formula (I) are those wherein R₄ is hydrogen or C₁₋₁₀ alkyl. More preferred is where R₄ is hydrogen or methyl.

Preferred R₁ moieties are 4-pyridyl and 4-quinolyl. More preferred is 4-pyridyl. A preferred substituent for all R₁ moieties is C₁₋₄ alkyl, more preferably

30 methyl. Most preferred for R₁ is a 2-alkyl-4-pyridyl, such as 2-methyl-4-pyridyl.

Preferred R₂ substituent groups on the phenyl ring are hydrogen or halogen. Preferred halogens are fluoro and chloro. Preferred ring substitution is in the 3- and 4-positions.

Preferred R₃ moieties are hydrogen, alkyl, aryl, and heteroaryl either attached directly to the imidazole ring, such as methyl, phenyl, pyridine, or pyrimidine, or by attachment thru a heteroatom, such as oxygen or sulfur, including but not limited to alkoxy, thioalkyl, benzyloxy, phenoxy, all optionally substituted by

5 Y terms. Additionally preferred moieties for R₃ are alkyl or phenyl substituted independently one or more time by halogen, $-(C(R_{10})_2)_nOR_8$, $-(C(R_{10})_2)_nS(O)_mR_{11}$, $-(C(R_{10})_2)_nSR_8$, $-(C(R_{10})_2)_nS(O)_mOR_8$, $-(C(R_{10})_2)_nS(O)_mNR_8R_9$, $-X_a-P(Z)-(X_aR_{13})_2$, $-(C(R_{10})_2)_nNR_8R_9$, $-(C(R_{10})_2)_nCO_2R_8$, $-(C(R_{10})_2)_nOC(O)-R_8$, $-(C(R_{10})_2)_nCONR_8R_9$, $-(C(R_{10})_2)_nNR_{10}C(=NCN)-NR_8R_9$, or $-(C(R_{10})_2)_nNR_{10}S(O)_mR_{11}$.

10

More preferably the R₃ substitution is $-(C(R_{10})_2)_nOR_8$, $-(C(R_{10})_2)_nS(O)_mR_{11}$, $-(C(R_{10})_2)_nNR_8R_9$, $-(C(R_{10})_2)_nCO_2R_8$, $-(C(R_{10})_2)_nS(O)_mNR_8R_9$, or $-(C(R_{10})_2)_nNR_{10}S(O)_mR_{11}$. Most preferably the

15 substituents are hydroxyl, methylthio, carboxylic acid, methylamino, N,N-dimethylaminomethyl, and the sulfonamide derivatives.

When R₃ is $-X_a-P(Z)-(X_aR_{13})_2$, the X_a moiety in $-X_a-P(Z)-(X_aR_{13})_2$ is preferably oxygen, or the moiety $-(C(R_{10})_2)_n$ wherein n is 0 to 2, Z and the

20 remaining X_a terms are oxygen.

A preferred subgenus of compounds for formula (I) is where 4-pyridyl, 2-alkyl-4-pyridyl, or 4-quinolyl; R₄ is hydrogen or methyl, R₁₀ is hydrogen or methyl, R₈ is hydrogen or alkyl, or where appropriate R₈ and R₉ cyclize to form a

25 5 membered saturated heterocyclic ring, R₂ is phenyl, or phenyl mono- or di-substituted with fluoro or chloro; R₃ is alkyl, phenyl or phenyl alkyl substituted with $-(C(R_{10})_2)_nOR_8$, $-(C(R_{10})_2)_nS(O)_mR_{11}$, $-(C(R_{10})_2)_nSR_8$, $-(C(R_{10})_2)_nS(O)_mOR_8$, $-(C(R_{10})_2)_nS(O)_mNR_8R_9$, $-X_a-P(Z)-(X_aR_{13})_2$, $-(C(R_{10})_2)_nNR_8R_9$, $-(C(R_{10})_2)_nCO_2R_8$, $-(C(R_{10})_2)_nOC(O)-R_8$, $-(C(R_{10})_2)_nCONR_8R_9$, $-(C(R_{10})_2)_nNR_{10}C(=NCN)-NR_8R_9$, or $-(C(R_{10})_2)_nNR_{10}S(O)_mR_{11}$.

30

In all instances herein where there is an alkenyl or alkynyl moiety as a substituent group, such as in R₅, R₇, R₈, R₉, or R₁₁ the unsaturated linkage, i.e.,

35 the vinylene or acetylene linkage is preferably not directly attached to the nitrogen, oxygen or sulfur moieties, for instance in Y as $-(C(R_{10})_2)_nNR_{10}C(Z)NR_8R_9$, $C(=NR_{10})-ZR_{11}$, or OR₈.

By the term "halo" as used herein is meant all halogens, i.e., chloro, fluoro, bromo and iodo.

By the term "C₁₋₁₀alkyl" or "alkyl" groups as used herein is meant to include both straight or branched chain radicals of 1 to 10 carbon atoms, unless the chain length is limited thereto, including, but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, and the like.

By the term "heterocyclic" as used herein, in any combination, such as "heterocyclic alkyl" is meant a 5-10 membered ring system in which one or more rings contain one or more heteroatoms selected from the group consisting of N, O, or S; such as but not limited to pyrrolidine, piperidine, piperazine, morpholine, imidazolidine, or pyrazolidine.

By the term "aryl" as used herein is meant phenyl, or naphthyl.

By the term "heteroaryl" as used herein, in any combination, such as "heteroaryloxy", is meant a 5-10 membered aromatic ring system in which one or more rings contain one or more heteroatoms selected from the group consisting of N, O or S; such as, but not limited, to quinoline, isoquinoline, pyridine, pyrimidine, oxazole, thiazole, thiadiazole, triazole, imidazole.

By the term "sulfinyl" as used herein is meant the oxide of the corresponding sulfide. By the term "thio" as used herein is meant the sulfide.

By the term "mammal" as used herein includes humans.

By the term "inhibiting the production of the cytokine (IL-1, IL-8 or TNF)" is meant

- a) a decrease of excessive *in vivo* levels of the cytokine (IL-1, IL-8 or TNF) in a human to normal levels or below normal levels by inhibition of the *in vivo* release of the cytokine (IL-1, IL-8 or TNF) by all cells, including but not limited to monocytes or macrophages;
- b) a down regulation, at the genomic level, of excessive *in vivo* levels of the cytokine (IL-1, IL-8 or TNF) in a human to normal levels or below normal levels; or
- c) a down regulation, by inhibition of the direct synthesis of the cytokine (IL-1, IL-8 or TNF) as a posttranslational event.

-10-

d) a down regulation, at the translational level, of excessive *in vivo* levels of the cytokine (IL-1, IL-8 or TNF) in a human to normal or sub-normal levels.

5 By the term "TNF mediated disease or disease state" is meant any and all disease states in which TNF plays a role, either by production of TNF itself, or by TNF causing another monokine to be released, such as but not limited to IL-1, or IL-6. A disease state in which IL-1, for instance is a major component, and whose production or action, is exacerbated or secreted in response to TNF, would therefore
10 be considered a disease stated mediated by TNF.

By the term "cytokine" as used herein is meant any secreted polypeptide that affects the functions of cells and is a molecule which modulates interactions between cells in the immune, inflammatory or hematopoietic response.
15 A cytokine includes, but is not limited to, monokines and lymphokines regardless of which cells produce them. For instance, a monokine is generally referred to as being produced and secreted by a mononuclear cell, such as a macrophage and/or monocyte but many other cells produce monokines, such as natural killer cells, fibroblasts, basophils, neutrophils, endothelial cells, brain astrocytes, bone marrow stromal cells,
20 epideral keratinocytes, and B- lymphocytes. Lymphokines are generally referred to as being produced by lymphocyte cells. Examples of cytokines include, but are not limited to, Interleukin-1 (IL-1), Interleukin-6 (IL-6), Tumor Necrosis Factor-alpha (TNF- α) and Tumor Necrosis Factor beta (TNF- β).

25 By the term "cytokine interfering or cytokine suppressive amount" is meant an effective amount of a compound of Formula (I) which will, cause a decrease in the *in vivo* levels of the cytokine to normal or sub-normal levels, when given to the patient for the prophylaxis or therapeutic treatment of a disease state which is exacerbated by, or caused by, excessive or unregulated cytokine production.

30 As used herein, the cytokine referred to in the phrase "inhibition of a cytokine, for use in the treatment of an HIV infected human" is a cytokine which is implicated in (a) the initiation and/or maintenance of T cell activation and/or activated T cell-mediated HIV gene expression and/or replication, and/or (b) any cytokine-mediated disease associated problem such as cachexia or muscle degeneration.
35

As TNF- β (also known as lymphotoxin) has close structural homology with TNF- α (also known as cachectin) and since each induces similar

biologic responses and binds to the same cellular receptor, both TNF- α and TNF- β are inhibited by the compounds of the present invention and thus are herein referred to collectively as "TNF" unless specifically delineated otherwise.

- 5 The compounds of the present invention may contain one or more asymmetric carbon atoms and may exist in racemic and optically active forms. All of these compounds are contemplated to be within the scope of the present invention.


Exemplified compounds of Formula (I) are:

- 1 0 1-(4-pyridyl)-2-(4-fluorophenyl)-4-phenylimidazole;
1-(4-pyridyl)-2-(4-fluorophenyl)-4-(4-hydroxyphenyl) imidazole;
1-(4-pyridyl)-2-(4-fluorophenyl)-4-(4-thiomethylphenyl) imidazole;
1-(4-pyridyl)-2-(4-fluorophenyl)-4-(4-methylsulfinylphenyl) imidazole;
1-(4-pyridyl)-2-(4-fluorophenyl)-4-(4-methylsulfonylphenyl) imidazole;
1 5 1-(4-pyridyl)-2-(4-fluorophenyl)-4-methylimidazole;
1-(4-pyridyl)-2-(4-N,N-dimethylaminomethylphenyl) imidazole;
1-(4-pyridyl)-2-(4-fluorophenyl)-4-(benzyloxy) imidazole;
1-(2-methyl-4-pyridyl)-4-(4-methylsulfinylphenyl) imidazole;
1-(2-methyl-4-pyridyl)-4-(4-thiomethylphenyl) imidazole; or
2 0 1-(2-methyl-4-pyridyl)-4-(3-chlorophenyl) imidazole.

METHODS OF PREPARATION:

- 2 5 Preparation of the compounds of Formula (I) can be carried out by one of skill in the art according to the procedures outlined in the Examples, *infra*. The preparation of any remaining compounds of Formula (I) not described therein may be prepared by the analogous processes disclosed herein.


-12-



Scheme I

- Compounds of this invention (wherein r is 0, and s is 1) may be prepared starting from the α -amino esters or nitriles 1 (illustrated in Scheme 1 for an aryl compound, but the method is also applicable to alkyl α -amino esters or nitriles). Compounds 1 are readily available from the corresponding aldehyde using the Strecker procedure or other standard methods. Acylation of 1 with an acid chloride affords the amides 2, which are converted to the aldehyde amides, 3, either directly by reduction with the appropriate hydride-based reagent, for example when $Z = \text{CN}$ or CO_2R by reduction with diisobutylaluminum hydride (DIBAL), or for $Z = \text{CO}_2\text{R}$ by first reduction of the ester to the alcohol, followed by subsequent oxidation back to the aldehyde oxidation state of compound 3. Alternatively, in some cases it may be more convenient to begin with compound 1 as the protected alcohol or aldehyde [$Z = \text{CH}_2\text{OR}$ or $\text{CH}(\text{OR})_2$] and subsequently deprotect and oxidize if needed to prepare 3 following the initial acylation step (1 to 2). Reaction of 3 with the required amino heterocycle (R_1 term) using acidic catalysis affords compound 4. The R_2 moiety represents the generic substitution terms as used for the R_2 moiety in formula (I). The R_2 and Y substituent groups are suitably unreactive moieties under the conditions noted above. Reactive substituent groups, such as the $\text{S}(\text{O})_m$ moiety of R_2 under conditions when Z is CO_2R and the Collins reaction is used, etc., are readily obvious to one skilled in the art.


-13-



Scheme II

- An additional method of imidazole synthesis utilizes the amides 5 prepared from readily available starting materials using standard coupling chemistry, such as that employed for the synthesis of peptides (Scheme II). In addition more vigorous methods such as the reaction of the ester or acid of the acyl partner and the appropriate heterocyclic amine (for the example in Scheme II, 4-aminopyridine) at elevated temperatures 100-300° C with or without a solvent may be used to prepare
5. Conversion of 5 to the imidoyl halide 6 followed by reaction with an α-amino nitrile (available as the initial product of the Strecker synthesis used in Scheme I) produces the amidine of structure 7. Reduction of the nitrile with a metal hydride reducing agent, preferably diisobutylaluminum hydride (DIBAL), affords the intermediate imine which can be cyclized, preferably with acid in a subsequent step to afford 8.

-14-



Scheme III

- Condensation of the imidoyl halide 6 (illustrated in scheme II) may also be performed with an aziridine to form the amidine derivative 9 (Scheme III). Reaction of 9 with an alkali halide in an appropriate solvent, preferably NaI in acetone yields the intermediate dihydroimidazole 10 which can be dehydrogenated by heating 10 in an inert solvent with a variety of metal catalysis or by oxidation, preferably using BaMnO₄ to produce the imidazole 8.
- If a 2-carboalkoxy aziridine is used, for example 2-carboethoxy aziridine, the resulting imidazole with R₃ = CO₂Et can be prepared. Basic hydrolysis (NaOH) of the ester affords the carboxylic acid which may be converted to the acid chloride by treatment with oxalyl chloride. Treatment of the acid chloride with an amine affords an amide, or with a metal azide affords the acyl azide. Thermal Beckman rearrangement of the acyl azide yields the isocyanate R₃ = -NCO, which can be reacted with either oxygen, nitrogen or sulfur nucleophiles to produce the corresponding carbamate, urea, or thiocarbamate, respectively. Alternatively, the Hunsdiecker reaction (treatment of the silver salt of the carboxylic acid with bromine) or variations thereof may be used to convert the acid to the rearranged bromide, R₃ = Br. Transmetalation of the bromide to the organolithium, using either n- or t-butyl lithium in an ethereal solvent, followed by addition of a dialkyl phosphorochloridate, such as dimethyl chlorophosphate, may be used to prepare the phosphonate ester, R₃ = P(=O)(OR)₂.

In Schemes I, II, and III the R_3 and Y terms may be an appropriately protected alcohol for example in Scheme III a silyl ether, such as t-butyldimethyl or t-butyldiphenyl, and in Schemes I and II an alkyl ether, such as methyl connected by an alkyl chain of variable link, $(C(R_{10})_2)_nR_3/Y$. Following cyclization to the imidazole the alcohol is deprotected using standard reaction conditions to afford the free alcohol. The alcohol may be oxidized to the carboxylic acid (chromic acid or pyridinium dichromate in dimethyl formamide) and subsequently converted to the ester (acid catalysis in the presence of an alcohol or carbonyl diimidazole followed addition of a basic solution of the alcohol). The alcohol may also be oxidized to the aldehyde (Swern's reagent or pyridinium chlorochromate in methylene chloride) and condensed with NH_3 , or a primary or secondary amine in the presence of $NaCNBH_3$, the Borch reductive amination procedure, to prepare the corresponding primary, secondary and tertiary amines, respectively. Alternatively the alcohol may be activated for displacement by either nitrogen, sulfur or phosphorus nucleophiles. For example, reaction of the alcohol with diisopropyl azodicarboxylate, triphenyl phosphine, and thioacetic acid produces the corresponding thioester which can be hydrolyzed to the thiol and oxidized to the sulfonic acid.

Additional derivatives which may be prepared from the above compounds are: $C(O)NR_8R_9$ from the $-CO_2CH_3$ by heating with or without catalytic metal cyanide, e.g. $NaCN$, and $HNNR_8R_9$ in CH_3OH ; $-OC(O)R_8$ from the $-OH$ with e.g., $ClC(O)R_8$ in pyridine; $-NR_{10}-C(S)NR_8R_9$ from $-NHR_{10}$ with an alkylisothiocyanate or thiocyanic acid; $NR_6C(O)OR_6$ from $-NHR_6$ with the alkyl chloroformate; $-NR_{10}C(O)NR_8R_9$ from the $-NHR_{10}$ by treatment with an isocyanate, e.g. $HN=C=O$ or $R_{10}N=C=O$; $-NR_{10}-C(O)R_8$ from the $-NHR_{10}$ by treatment with $Cl-C(O)R_8$ in pyridine; $-C(=NR_{10})NR_8R_9$ from $-C(NR_8R_9)SR_8$ with $H_3NR_8^+OAc^-$ by heating in alcohol; $-C(NR_8R_9)SR_8$ from $-C(S)NR_8R_9$ with R_6-I in an inert solvent, e.g. acetone; $-C(S)NR_8R_9$ where R_8 or R_9 is not hydrogen from $C(S)NH_2$ with HNR_8R_9 , $C(=NCN)-NR_8R_9$ from $-C(=NR_8R_9)-SR_8$ with NH_2CN by heating in anhydrous alcohol, alternatively from $C(=NH)-NR_8R_9$ by treatment with $Br-CN$ and $NaEtO^-$ in $EtOH$; $NR_{10}-C(=NCN)SR_8$ from NHR_{10} by treatment with $(R_8S)_2C=NCN$; $-NR_{10}SO_2R_8$ from NHR_{10} by treatment with $ClSO_2R_8$ by heating in pyridine; $-NR_{10}C(S)R_8$ from $-NR_{10}C(O)R_8$ by treatment with Lawesson's reagent [2,4-bis(4-methoxyphenyl)-1,3,2,4-dithiadiphosphetane-2,4-disulfide]; $-NR_{10}SO_2CF_3$ from NHR_6 with triflic anhydride and base; $NR_{10}C(O)-C(O)-OR_8$ from $-NHR_{10}$ with, e.g. methyloxalyl chloride and a base such as triethylamine; $-NR_{10}C(O)-C(O)-NR_8R_9$ from $-NR_{10}C(O)-C(O)-OR_8$ with

HNR₈R₇₉; 1-(NR₁₀)-2-imidazolyl from -C(=NH)NHR₁₀ by heating with 2-chloroacetaldehyde in chloroform.

5

SYNTHETIC EXAMPLES

The following examples are illustrative and are not limiting of the compounds of this invention.

EXAMPLE 1

1-(4-Pyridyl)-2-(4-fluorophenyl)-4-phenylimidazole

10

Ethyl phenylglycine hydrochloride. To a mixture of phenylglycine (15.00 gram (hereinafter g.), 0.1 mole (hereinafter mol)) in EtOH (100 mL (hereinafter mL)) was added 20% ethanolic HCl (30 mL). The mixture was heated at reflux for about 20 hours (hereinafter h.), then allowed to cool. The solvent was removed *in vacuo*, and the residue was used without further purification.

15

N-(4-Fluorobenzoyl)phenylglycine ethyl ester. To a solution of ethyl phenylglycine hydrochloride (prepared above) in CH₃CN (60 mL) were added 4-fluorobenzoyl chloride (25.4 g, 0.16 mol) and pyridine. The resulting mixture was stirred at room temperature for about 5.5 h, then was partitioned between aqueous NaHCO₃ and EtOAc. The organic extract was washed successively with 10% aqueous NaOH, 3 N HCl and saturated aqueous NaCl. The solvent was removed *in vacuo*, and the residue was crystallized from CH₂Cl₂/hexanes to afford the title compound (19 g, 63%).

20

25

4-Fluoro-N-(2-hydroxy-1-phenyl)ethylbenzamide. To a solution of N-(4-fluorobenzoyl)phenylglycine ethyl ester (1.56 g, 5.2 mmol) in THF (15 mL) was added sodium borohydride (0.50 g, 12.9 mmol), followed by MeOH (4.2 mL). The resulting mixture was allowed to stir for about 75 min, during which time additional sodium borohydride was added. The mixture was poured into H₂O and concentrated under reduced pressure. The residue was partitioned between saturated aqueous NaCl and EtOAc. The organic extract was concentrated *in vacuo*, and the residue was purified by flash chromatography, eluting with 25% EtOAc/hexanes to afford the title compound (0.80 g, 60%).

30

35

4-Fluoro-N-(2-oxo-1-phenyl)ethylbenzamide. To a solution of pyridine (1.6 mL, 19.30 mmol) in CH₂Cl₂ (18 mL) was added, portionwise, CrO₃ (1.16 g, 11.58 mmol). Upon completion of the addition, the mixture was allowed to stir for about

-17-

30 min, at which time was added a solution of 4-fluoro-N-(2-hydroxy-1-phenyl)ethylbenzamide (0.50 g, 1.93 mmol) in CH₂Cl₂ (35 mL). The resulting mixture was allowed to stir for about 5 min, then was filtered through a pad of florisil and concentrated under reduced pressure to afford the title compound.

5

1-(4-Pyridyl)-2-(4-fluorophenyl)-4-phenylimidazole. To a solution containing 4-fluoro-N-(2-oxo-1-phenyl)ethylbenzamide (0.15 g, 0.58 mmol) and 4-aminopyridine (0.06 g, 0.65 mmol) in toluene (10 mL) was added p-toluenesulfonic acid (0.22 g, 1.20 mmol). The mixture was heated at reflux with azeotropic removal of H₂O.

10 After heating at reflux for about 1 h, the mixture was allowed to cool and was partitioned between aqueous NaHCO₃ and EtOAc. The organic extract was concentrated under reduced pressure and purified by flash chromatography, eluting with a solvent gradient of 1 : 5 to 1 : 1 EtOAc/ hexanes. The title compound was obtained (0.04 g, 17%) as a light yellow solid. m.p. 90 - 92°C

15

EXAMPLE 2

1-(4-Pyridyl)-2-(4-fluorophenyl)-4-(4-hydroxyphenyl)imidazole

Ethyl 4-hydroxyphenylglycine, hydrochloride. To a suspension of 4-hydroxyphenylglycine (18.00 g, 0.11 mol) in EtOH (100 mL) was added 20% ethanolic HCl (30 mL). The mixture was heated at reflux for 14 h, then was allowed to cool and was concentrated under reduced pressure. The residue was partitioned between saturated aqueous NaHCO₃ and EtOAc, and the organic extract was concentrated *in vacuo* to afford the title compound (15.00 g, 70%).

25

N-(4-Fluorobenzoyl)-2-[4-oxy-(4-fluorobenzoyl)phenyl]glycine, ethyl ester. To a suspension of ethyl 4-hydroxyphenylglycine, hydrochloride (prepared above) in CH₃CN were added 4-fluorobenzoyl chloride (20 mL, 0.17 mol) and pyridine (15.5 mL, 0.20 mol). The resulting mixture was stirred at room temperature for 5 min, then was partitioned between aqueous NaHCO₃ and EtOAc. The organic extract was washed successively with 3 N HCl, saturated aqueous NaCl, 5% aqueous NaHCO₃ and saturated aqueous NaCl. The solvent was removed *in vacuo* to afford the title compound.

30

35 4-Fluoro-N-[1-(4-hydroxyphenyl)-2-hydroxy]ethylbenzamide. To a solution of N-(4-fluorobenzoyl)-2-[4-oxy-(4-fluorobenzoyl)phenyl]glycine, ethyl ester (1.00 g, 2.27 mmol) in THF (6 mL) was added sodium borohydride (0.22 g, 5.70 mmol). The mixture was warmed to 55°C and MeOH (1.9 mL) was added over 10 min.

Upon completion of the addition, the mixture was poured into H₂O and concentrated under reduced pressure. The residue was partitioned between saturated aqueous NaCl and EtOAc. The organic extract was concentrated *in vacuo*, and the residue was purified by flash chromatography, eluting with 1 : 1 EtOAc/ hexanes to afford the title compound (0.46 g, 73%).

N-[1-(4-Benzyloxyphenyl-2-hydroxy)ethyl]-4-fluorobenzamide. To a solution of 4-fluoro-N-[1-(4-hydroxyphenyl-2-hydroxy)ethyl]benzamide (0.40 g, 1.45 mmol) in acetone were added potassium carbonate (0.30 g, 2.18 mmol) and benzyl bromide (0.29 g, 1.75 mmol). The resulting mixture was heated at reflux for 20 h, then was allowed to cool and was concentrated under reduced pressure. The residue was purified by flash chromatography, eluting with 1 : 1 EtOAc/ hexanes to afford the title compound (0.50 g, 94%).

N-[1-(4-Benzyloxyphenyl-2-oxo)ethyl]-4-fluorobenzamide. To a solution of pyridine (1.1 mL, 12.8 mmol) in CH₂Cl₂ (10 mL) was added, portionwise, CrO₃ (0.78 g, 7.73 mmol). Upon completion of the addition, the mixture was allowed to stir for 30 min, at which time was added a solution of N-[1-(4-benzyloxyphenyl-2-hydroxy)ethyl]-4-fluorobenzamide (0.47 g, 1.28 mmol) in CH₂Cl₂ (35 mL). The resulting mixture was allowed to stir for 25 min, then was filtered through a pad of florisil and concentrated under reduced pressure to afford the title compound.

1-(4-Pyridyl)-2-(4-fluorophenyl)-4-(4-benzyloxyphenyl)imidazole. To a solution containing N-[1-(4-benzyloxyphenyl-2-oxo)ethyl]-4-fluorobenzamide (0.38 g, 1.00 mmol) and 4-aminopyridine (0.11 g, 1.17 mmol) in toluene was added p-toluenesulfonic acid (0.42 g, 2.20 mmol). The mixture was heated at reflux with azeotropic removal of H₂O. After heating at reflux for 1 h, the mixture was allowed to cool and was partitioned between aqueous NaHCO₃ and EtOAc. The organic extract was concentrated under reduced pressure and purified by flash chromatography, eluting with a solvent gradient of 1 : 5 to 1 : 2 EtOAc/ hexanes. The title compound was obtained (0.06 g, 14%) and was crystallized from EtOAc/ hexanes.

1-(4-Pyridyl)-2-(4-fluorophenyl)-4-(4-hydroxyphenyl)imidazole. A mixture containing 1-(4-pyridyl)-2-(4-fluorophenyl)-4-(4-benzyloxyphenyl)imidazole (0.13 g, 0.3 mmol) and 10% palladium on activated carbon (100 mg) in EtOAc was stirred under an atmosphere of H₂ for 10 h, at which time the reaction mixture was filtered through a pad of Celite. The filtrate was concentrated under reduced pressure, and the residue was purified by flash chromatography, eluting with 1 : 1 EtOAc/ hexanes.

The material which was isolated was crystallized from EtOAc/ hexanes to afford the title compound (0.07 g, 70%). m.p. 230 - 231°C.

EXAMPLE 3

5 1-(4-Pyridyl)-2-(4-fluorophenyl)-4-(4-thiomethylphenyl) imidazole. The compound of Example 3 was produced by the process according to Scheme I; converting 4-thiomethylbenzaldehyde to the amino nitrile and condensing this with 4-fluorobenzoyl chloride. Reduction of the nitrile to the aldehyde was followed by condensation with
10 4-amino pyridine according to the method of examples 1 and 2 to afford the title compound, m.p. 192-196°C.

EXAMPLE 4

1-(4-Pyridyl)-2-(4-fluorophenyl)-4-(4-methylsulfinylphenyl) imidazole. Oxidation of
15 1-(4-pyridyl)-2-(4-fluorophenyl)-4-(4-thiomethylphenyl) imidazole of Example 3 with K₂S₂O₈ in acetic acid followed by chromatography on silica and recrystallization afforded the titled sulfoxide, m.p. 201-203°C.

EXAMPLE 5

1-(4-pyridyl)-2-(4-fluorophenyl)-4-methylimidazole. The compound of Example 5
20 was produced by the process according to Scheme III, employing methyl-aziridine and the imidoyl chloride prepared from the amide formed by condensation of 4-amino pyridine and 4-fluorobenzoyl chloride. Cyclization and dehydrogenation of this adduct affords the title imidazole as a white solid, m/e (rel. int.): 254 [(M+H)⁺].

EXAMPLE 6

1-(2-methylpyrid-4-yl)-2-(4-fluorophenyl)-4-(4-thiomethylphenyl)imidazole. This
25 compound was produced by the process according to Scheme I; converting 4-thiomethylbenzaldehyde to the amino nitrile and condensing this with 4-fluorobenzoyl chloride. Reduction of the nitrile to the aldehyde was followed by condensation with
30 2-methyl-4-amino pyridine according to the method of examples 1 and 2 to afford the title compound, m.p. 144-146°C.

EXAMPLE 7

1-(2-methylpyrid-4-yl)-2-(4-fluorophenyl)-4-(4-methylsulfinylphenyl)imidazole.
35 Oxidation of 1-(2-methylpyrid-4-yl)-2-(4-fluorophenyl)-4-(4-thiomethylphenyl)imidazole of Example 7 with K₂S₂O₈ in acetic acid followed by chromatography on silica and recrystallization afforded the titled sulf oxide, m.p. 160-163°C.

By analogous methods to those described above in Example 1 to 7, and in Schemes I to III herein the following compounds may be produced:

Example 8 - 1-(4-pyridyl)-2-(4-N,N-dimethylaminomethylphenyl) imidazole.

5 Example 9 - 1-(4-pyridyl)-2-(4-fluorophenyl)-4-(benzyloxy) imidazole.

Example 10 - 1-(2-methyl-4-pyridyl)-4-(3-chlorophenyl) imidazole.

METHODS OF TREATMENT

1 0 The compounds of Formula (I) can be used in the manufacture of a medicament for the prophylactic or therapeutic treatment of any disease state in a human, or other mammal, which is exacerbated or caused by excessive or unregulated excessive or unregulated cytokine production, more specifically IL-1, IL-8 or TNF production, by such mammal's cell, such as but not limited to
1 5 monocytes and/or macrophages.

Compounds of Formula (I) are capable of inhibiting proinflammatory cytokines, such as IL-1, IL-8 and TNF and are therefore of use in therapy. IL-1, IL-8 and TNF affect a wide variety of cells and tissues and these cytokines, as well as other leukocyte derived cytokines, are important and critical inflammatory mediators
2 0 of a wide variety of disease states and conditions. The inhibition of these pro-inflammatory cytokines is of benefit in controlling, reducing and alleviating many of these diseases.

The compounds of Formula (I) are administered in an amount sufficient to inhibit TNF production such that it is regulated down to normal levels, or
2 5 in some case to subnormal levels, so as to ameliorate or prevent the disease state. Abnormal levels of TNF, for the present invention, constitute levels of 1) free (not cell bound) TNF, greater than or equal to 1 picogram per ml; 2) any cell associated TNF; or 3) the presence of TNF mRNA above basal levels in cells or tissues in which TNF is produced.

3 0 The compounds of Formula (I) may be used in the treatment of any disease states mediated by excessive or unregulated TNF production, such as but not limited to rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, adult respiratory distress syndrome, cerebral malaria,
3 5 chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoidosis, bone resorption diseases, such as osteoporosis, reperfusion injury, graft vs. host reaction, allograft rejections, fever and myalgias due to infection, such as influenza, cachexia secondary to infection or malignancy, cachexia, secondary to acquired immune

deficiency syndrome (AIDS), AIDS, ARC (AIDS related complex), keloid formation, scar tissue formation, Crohn's disease, ulcerative colitis, pyresis, AIDS and other viral infections, such as cytomegalia virus (CMV), influenza virus, and the herpes family of viruses such as Herpes Zoster or Simplex I and II.

5 The compounds of Formula (I) may also be used topically as well in the treatment or prophylaxis of inflammatory topical disease states mediated or exacerbated by excessive TNF production respectively, such as for rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions, inflamed joints, eczema, psoriasis or other inflammatory skin conditions
10 such as sunburn; inflammatory eye conditions including conjunctivitis; pyresis, pain and other conditions associated with inflammation.

 The compounds of Formula (I) may also be used in association with the veterinary field for treatment of TNF mediated diseases such as viral infections. Examples of such viruses include but are not limited to, feline immunodeficiency
15 virus (FIV) or other retroviral infection such as equine infectious anaemia virus, caprine arthritis virus, visna virus, maedi virus and other lentiviruses.

 Interleukin-1 (IL-1) has been demonstrated to mediate a variety of biological activities thought to be important in immunoregulation and other physiological conditions such as inflammation [See, e.g., Dinarello et al., Rev.
20 Infect. Disease, 6, 51 (1984)]. The myriad of known biological activities of IL-1 include the activation of T helper cells, induction of fever, stimulation of prostaglandin or collagenase production, neutrophil chemotaxis, induction of acute phase proteins and the suppression of plasma iron levels.

 The discovery that the compounds of Formulas (I) are inhibitors of cytokines, specifically IL-1 is based upon the effects of the compounds of Formulas (I) on the production of the IL-1 in vitro, on the human monocyte, the assays of which are described herein.

 There are many disease states in which excessive or unregulated IL-1 production is implicated in exacerbating and/or causing the disease. These include
30 rheumatoid arthritis, osteoarthritis, endotoxemia and/or toxic shock syndrome, other acute or chronic inflammatory disease states such as the inflammatory reaction induced by endotoxin or inflammatory bowel disease; tuberculosis, atherosclerosis, muscle degeneration, cachexia, psoriatic arthritis, Reiter's syndrome, rheumatoid arthritis, gout, traumatic arthritis, rubella arthritis, and acute synovitis. Recent
35 evidence also links IL-1 activity to diabetes and pancreatic B cells.

 Dinarello, J. Clinical Immunology, 5 (5), 287-297 (1985), reviews the biological activities which have been attributed to IL-1. It should be noted that some of these effects have been described by others as indirect effects of IL-1.

The compounds of Formula (I) have also been shown to inhibit the production of Interleukin-8 (NAP-1/IL-8). IL-8 is a chemotactic factor first identified and characterized in 1987. IL-8 is produced by several cell types including mononuclear cells, fibroblasts, endothelial cells, and keratinocytes. Many different names have been applied to IL-8, such as neutrophil attractant/activation protein-1 (NAP-1), monocyte derived neutrophil chemotactic factor (MDNCF), neutrophil activating factor (NAF), and T-cell lymphocyte chemotactic factor.

There are many disease states in which excessive or unregulated IL-8 production is implicated in exacerbating and/or causing the disease. These diseases are characterized by massive neutrophil infiltration such as, psoriasis, inflammatory bowel disease, asthma, cardiac and renal reperfusion injury, adult respiratory distress syndrome, thrombosis and glomerulonephritis. All of these diseases have the association of increased IL-8 production, which is responsible for the chemotaxis of neutrophils into the inflammatory site. In contrast to other inflammatory cytokines (IL-1, TNF, and IL-6) IL-8 has the unique property of promoting neutrophil chemotaxis. Therefore, the inhibition of IL-8 production would lead to a direct reduction in the neutrophil infiltration.

The discovery of a compound which specifically inhibits IL-1, IL-8, and TNF production will not only contribute to the understanding of how this molecule is synthesized, processed and secreted, but will also provide a therapeutic approach for diseases in which excessive or unregulated IL-1 and TNF production is implicated.

PHARMACEUTICAL COMPOSITIONS

In order to use a compound of the Formula (I) or a pharmaceutically acceptable salt thereof for the treatment of humans and other mammals it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.

This invention, therefore, also relates to a pharmaceutical composition comprising an effective, non-toxic amount of a compound of Formulas (I) and a pharmaceutically acceptable carrier or diluent. The compounds of Formula (I) are administered in conventional dosage forms prepared by combining a compound of Formula (I) with standard pharmaceutical carriers according to conventional procedures. The compounds of Formula (I) may also be administered in conventional dosages in combination with a known, second therapeutically active compound. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation.

The pharmaceutical carrier employed may be, for example, either a solid or liquid. Exemplary of solid carriers are lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like. Exemplary of liquid carriers are syrup, peanut oil, olive oil, water and the like. Similarly, the carrier or diluent may include time delay material well known to the art, such as glyceryl mono-stearate or glyceryl distearate alone or with a wax.

A wide variety of pharmaceutical forms can be employed. Thus, if a solid carrier is used, the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or in the form of a troche or lozenge. The amount of solid carrier will vary widely but preferably will be from about 25 mg. to about 1 g. When a liquid carrier is used, the preparation will be in the form of a syrup, emulsion, soft gelatin capsule, sterile injectable liquid such as an ampule or nonaqueous liquid suspension.

The compounds of Formula (I) may be administered topically. Thus, the compounds of Formula (I) may be administered topically in the treatment or prophylaxis of inflammation or other cytokine related diseases in a mammal, such as rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions, inflamed joints, eczema, psoriasis or other inflammatory skin conditions such as sunburn; inflammatory eye conditions including conjunctivitis; pyresis, pain and other conditions associated with inflammation.

The amount of a compound of Formula (I), for all methods of use disclosed herein, required for therapeutic effect on topical administration will, of course, vary with the compound chosen, the nature and severity of the inflammatory condition, whether eicosanoid or cytokine mediated, and the animal undergoing treatment, and is ultimately at the discretion of the physician. A suitable, topical, anti-inflammatory dose of an active ingredient, i.e., a compound of Formula (I) is 0.1 mg to 150 mg, administered one to four, preferably two or three times daily.

By topical administration is meant non-systemic administration and includes the application of a compound of Formula (I) externally to the epidermis, to the buccal cavity and instillation of such a compound into the ear, eye and nose, and where the compound does not significantly enter the blood stream. By systemic administration is meant oral, intravenous, intraperitoneal and intramuscular administration.

While it is possible for an active ingredient to be administered alone as the raw chemical, it is preferable to present it as a pharmaceutical formulation. The active ingredient may comprise, for topical administration, from 0.001% to 10% w/w, e.g. from 1% to 2% by weight of the formulation although it may comprise as

much as 10% w/w but preferably not in excess of 5% w/w and more preferably from 0.1% to 1% w/w of the formulation.

The topical formulations of the present invention comprise an active ingredient together with one or more acceptable carrier(s) therefor and optionally any other therapeutic ingredient(s). The carrier(s) must be 'acceptable' in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of inflammation such as liniments, lotions, creams, ointments or pastes, and drops suitable for administration to the eye, ear or nose.

Drops according to the present invention may comprise sterile aqueous or oily solutions or suspensions and may be prepared by dissolving the active ingredient in a suitable aqueous solution of a bactericidal and/or fungicidal agent and/or any other suitable preservative, and preferably including a surface active agent. The resulting solution may then be clarified by filtration, transferred to a suitable container which is then sealed and sterilized by autoclaving or maintaining at 98-100°C. for half an hour. Alternatively, the solution may be sterilized by filtration and transferred to the container by an aseptic technique. Examples of bactericidal and fungicidal agents suitable for inclusion in the drops are phenylmercuric nitrate or acetate (0.002%), benzalkonium chloride (0.01%) and chlorhexidine acetate (0.01%). Suitable solvents for the preparation of an oily solution include glycerol, diluted alcohol and propylene glycol.

Lotions according to the present invention include those suitable for application to the skin or eye. An eye lotion may comprise a sterile aqueous solution optionally containing a bactericide and may be prepared by methods similar to those for the preparation of drops. Lotions or liniments for application to the skin may also include an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moisturizer such as glycerol or an oil such as castor oil or arachis oil.

Creams, ointments or pastes according to the present invention are semi-solid formulations of the active ingredient for external application. They may be made by mixing the active ingredient in finely-divided or powdered form, alone or in solution or suspension in an aqueous or non-aqueous fluid, with the aid of suitable machinery, with a greasy or non-greasy basis. The basis may comprise hydrocarbons such as hard, soft or liquid paraffin, glycerol, beeswax, a metallic soap; a mucilage; an oil of natural origin such as almond, corn, arachis, castor or live oil; wool fat or its derivatives, or a fatty acid such as steric or oleic acid together with an alcohol such as propylene glycol or macrogels. The formulation may

-25-

incorporate any suitable surface active agent such as an anionic, cationic or non-ionic surfactant such as sorbitan esters or polyoxyethylene derivatives thereof. Suspending agents such as natural gums, cellulose derivatives or inorganic materials such as siliceous silicas, and other ingredients such as lanolin, may also be included.

5 The methods of the subject invention may be carried out by delivering the monokine activity interfering agent parenterally. The term 'parenteral' as used herein includes intravenous, intramuscular, subcutaneous intranasal, intrarectal, intravaginal or intraperitoneal administration. The subcutaneous and intramuscular forms of parenteral administration are generally preferred. Appropriate dosage forms
10 for such administration may be prepared by conventional techniques.

For all methods of use disclosed herein for the compounds of Formulas (I), the daily oral dosage regimen will preferably be from about 0.05 to about 80 mg/kilogram of total body weight, preferably from about 0.1 to 30 mg/kg, more preferably from about 0.5 mg to 15 mg. The daily parenteral dosage regimen
15 will preferably be from about 0.05 to about 80 mg per kilogram (kg) of total body weight, preferably from about 0.1 to about 30 mg/kg, and more preferably from about 0.5 mg to 15mg/kg.

The compounds of Formula (I) may also be administered by inhalation. By "inhalation" is meant intranasal and oral inhalation administration.
20 Appropriate dosage forms for such administration, such as an aerosol formulation or a metered dose inhaler, may be prepared by conventional techniques. The preferred daily dosage amount of a compound of Formula (I) administered by inhalation for all methods disclosed herein, is from about .01 mg/kg to about 1 mg/kg per day.

It will be recognized by one of skill in the art that the form and
25 character of the pharmaceutically acceptable carrier or diluent is dictated by the amount of active ingredient with which it is to be combined, the route of administration and other well-known variables.

It will also be recognized by one of skill in the art that the optimal quantity and spacing of individual dosages of a compound of Formula (I) or a
30 pharmaceutically acceptable salt thereof will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular patient being treated, and that such optimums can be determined by conventional techniques.

It will also be appreciated by one of skill in the art that the optimal
35 course of treatment, i.e., the number of doses of a compound of Formula (I) or a pharmaceutically acceptable salt thereof given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests.

EXAMPLES

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent.

- 5 The following Examples are, therefore, to be construed as merely illustrative and not a limitation of the scope of the present invention in any way.

EXAMPLE A

Inhibitory Effect of compounds of Formula (I) on 10 in vitro IL-1 Production by Human Monocytes

The effects of compounds of Formula (I) on the in vitro production of IL-1 by human monocytes was examined using the following protocol.

- 15 Bacterial lipopolysaccharide (LPS) was used to induce IL-1 production by human peripheral blood monocytes. IL-1 activity was measured by its ability to stimulate a Interleukin 2 (IL-2) producing cell line (EL-4) to secrete IL-2, in concert with A23187 ionophore, according to the method of Simon et al., J. Immunol. Methods, 84, 85, (1985). Human peripheral blood monocytes were isolated and purified from either fresh blood preparations from volunteer donors, or from blood
20 bank buffy coats, according to the procedure of Colotta et al., J. Immunol., 132, 936 (1984). 1×10^6 of such monocytes were plated in 24-well plates at a concentration of 1-2 million/ml per well. The cells were allowed to adhere for 2 hours, after which time non-adherent cells were removed by gentle washing. Test compounds were then added to the cells for 1 hour (hr) before the addition of lipopolysaccharide (50 ng/ml),
25 and the cultures were incubated at 37°C for an additional 24 hours. At the end of the incubation period, culture supernatants were removed and clarified of cells and all debris. Culture supernatants were immediately assayed for IL-1 biological activity in the manner described above, as well as for prostaglandin and/or leukotriene concentrations by radioimmunoassay.

- 30 The compounds of Formula (I), Examples 1, 2, and 5 are potent inhibitors of in vitro IL-1 production by human monocytes having IC₅₀'s between 0.1 µM and 5 µM. The compounds of Examples 3, and 4 exhibited an IC₅₀ of > 5µM.

- 35 Based on the widely held belief of the role of unmodulated (i.e., excessive) in vivo IL-1 production in causing or aggravating inflammatory responses and their disease states (see, e.g., Fontana et al., supra; Wood et al., supra; Akejiima and Dinarello, supra; Habicht and Beck, supra; Chesque et al., supra; Benjamin et al., supra; and Dinarello, supra), and based on the fact that compounds of Formula

-27-

(I) inhibit in vitro IL-1 production by human macrophages and/or monocytes, the compounds of Formula (I) will inhibit the in vivo IL-1 production by monocytes and/or macrophages in a human in need thereof when used according to the method of the subject invention.

5

UTILITY EXAMPLE B

Inhibitory Effect of compounds of Formula (I) on
in vitro TNF production by Human Monocytes

Section I: Assay set-up

1 0 The effects of compounds of Formula (I) on the in vitro production of
TNF by human monocytes was examined using the following protocol.

Human peripheral blood monocytes were isolated and purified from
either blood bank buffy coats or plateletpheresis residues, according to the procedure
of Colotta, R. et al., J. Immunol., 132(2):936 (1984). The monocytes were plated at
1 5 a density of 1×10^6 cells/ml medium/well in 24-well multi-dishes. The cells were
allowed to adhere for 1 hour after which time the supernatant was aspirated and 1 ml
fresh medium (RPMI-1640 (Whitaker Biomedical Products, Whitaker, CA)
containing 1% fetal calf serum and penicillin and streptomycin at 10 units/ml was
added. The cells were incubated for 45 minutes in the presence or absence of test
2 0 compounds at 1nM-10uM dose ranges (compounds were solubilized in Dimethyl-
sulfoxide/Ethanol such that the final solvent concentration in the culture medium was
0.5% Dimethyl sulfoxide/0.5% Ethanol). Bacterial lipopolysaccharide (E. coli
055:B5 [LPS] from Sigma Chemicals Co.) was then added at 100 ng/ml in 10 ml
Phosphate Buffered Saline (PBS) and cultures incubated for 16-18 hours at 37°C in a
2 5 5% CO₂ incubator. At the end of the incubation period, culture supernatants were
removed from the cells, centrifuged at 3000 revolutions per minute (rpm) to remove
cell debris and .05 ml of the supernatant assayed for TNF activity using the
radioimmunoassay described below.

3 0 Section II: Radioimmunoassay procedure for TNF activity

The assay buffer consisted of 0.01M NaPO₄, 0.15M NaCl, 0.025M
EDTA and 0.1% sodium azide at pH 7.4. Human recombinant TNF (rhTNF)
obtained using the procedure of Chen et al., Nature, 330:581-583 (1987) was
iodinated by a modified Chloramine-T method described in Section III below. To
3 5 samples (50 µl culture supernatants) or rhTNF standards, a 1/9000 dilution of
polyclonal rabbit anti-rhTNF (Genzyme, Boston, MA) and 8000 cpm of ¹²⁵I-TNF
was added in a final volume of 400 µl buffer and incubated overnight (18 hours) at
4°C. Normal rabbit serum and goat anti-rabbit IgG (Calbiochem) were titrated against

-28-

each other for maximum precipitation of the anti-rhTNF. The appropriate dilutions of carrier normal rabbit serum (1/200), goat anti-rabbit IgG (1/4) and 25 Units heparin (Calbiochem) were allowed to precipitate and 200 µl of this complex was added per assay tube and incubated overnight at 4°C. Tubes were centrifuged for 30 minutes at 2000 rpm, supernatants were carefully aspirated, and radioactivity associated with the pellets measured in a Beckman Gamma 5500 counter. The logit-log linear transformation curve was used for the calculations. The concentrations of TNF in the samples was read of a standard curve of rhTNF that was linear in the 157 to 20,000 pg/ml range.

1 0

Section III: Radioiodination of rhTNF

Iodination of rhTNF was performed using a modified chloramine-T method of Frolik et al., J. Biol. Chem., 259:10995-11000 (1984). Briefly, 5 mg of rhTNF in 5 ml of 20MM Tris pH 7.5, was diluted with 15 ml of 0.5M KPO₄ and 10 ml of carrier free ¹²⁵I(100mCi/ml;ICN). To initiate the reaction, a 5ml aliquot of a 100mg/ml (aqueous) chloramine-T solution was added. After 2 minutes at room temperature, an additional 5 ml aliquot was added followed 1.5 minutes later by a final 5 ml addition of chloramine-T. The reaction was stopped 1 minute later by sequential addition of 20 ml of 50mM Sodium Metabisulfite, 100 ml of 120mM Potassium Iodide and 200 ml of 1.2 mg/ml Urea. The contents were mixed and the reaction mixture was passed over a pre-packed Sephadex G-25 column (PD 10 Pharmacia), equilibrated and eluted with Phosphate Buffered Saline pH 7.4 containing 0.25% gelatin. The peak radioactivity containing fractions were pooled and stored at -20°C. Specific activity of ¹²⁵I-TNF was 80-100 mCi/mg protein. Biological activity of iodinated TNF was measured by the L929 cytotoxicity assay of Neale, M.L. et al., Eur. J. Can. Clin. Oncol., 25(1):133-137 (1989) and was found to be 80% that of unlabeled TNF.

Section IV: Measurement of TNF- ELISA:

Levels of TNF were also measured using a modification of the basic sandwich ELISA assay method described in Winston et al., Current Protocols in Molecular Biology, Page 11.2.1, Ausubel et al., Ed. (1987) John Wiley and Sons, New York, USA. The ELISA employed a murine monoclonal anti-human TNF antibody, described below, as the capture antibody and a polyclonal rabbit anti-human TNF, described below, as the second antibody. For detection, a peroxidase-conjugated goat anti-rabbit antibody (Boehringer Mannheim, Indianapolis, Indiana, USA, Catalog # 605222) was added followed by a substrate for peroxidase (1mg/ml

orthophenylenediamine with 0.1% urea peroxide). TNF levels in samples were calculated from a standard curve generated with recombinant human TNF produced in *E. Coli* (obtained from SmithKline Beecham Pharmaceuticals, King of Prussia, PA, USA).

5

Section V: Production of anti-human TNF antibodies:

Monoclonal antibodies to human TNF were prepared from spleens of BALB/c mice immunized with recombinant human TNF using a modification of the method of Kohler and Millstein, *Nature* 256:495 (1975), the entire disclosure of which is hereby incorporated by reference. Polyclonal rabbit anti-human TNF antibodies were prepared by repeated immunization of New Zealand White (NZW) rabbits with recombinant human TNF emulsified in complete Freund's adjuvant (DIFCO, IL., USA).

1 5 Results:

The compounds of Formula (I), Examples 1 and 2 both demonstrated an IC₅₀'s between 0.5 μ M and 3.5 μ M in the above described assay. The exact mechanism by which any compound of Formula (I) inhibits *in vitro* TNF production by monocytes is not presently known. This inhibitory activity does not seem to correlate with the property of any of the compounds of Formula (I) in mediating arachidonic acid metabolism inhibition since other nonsteroidal antiinflammatory drugs with potent cyclooxygenase and/or lipoxygenase inhibitory activity do not inhibit TNF production at nontoxic doses. Furthermore, the ability of a compound to inhibit production of prostaglandin and/or leukotriene synthesis does not mean that it will necessarily also inhibit TNF production.

EXAMPLE C

Inhibitory Effect of compounds of Formula (I) on IL-8 Production

3 0

The effects of compounds of Formula (I) on the inhibition of IL-8 production from Human Umbilical Vein Endothelial cells is examined using the following protocol.

Primary human umbilical cord endothelial cells (HUVEC) are obtained from Cell Systems (Kirland, WA) and maintained in culture medium supplemented with 15% fetal bovine serum and 1% CS-HBGF consisting of α FGF and heparin. Cells are then diluted 20-fold before being plated (250 μ l) into gelating coated 96-well plates. Prior to use, culture medium is replaced with fresh medium (200 μ l). 25 μ l of

-30-

either buffer or test compounds at the appropriate concentration is added to each well in quadruplicate wells. This is followed immediately by the addition of 25 μ l of the compounds of Formula (I) at concentrations between 1-10 μ M. The plates are allowed to incubate for the appropriate time, as indicated in a humidified incubator at 37°C with 5% CO₂. At the end of the incubation period, supernatant is removed and assayed for IL-8 concentration using an IL-8 ELISA kit obtained from R&D Systems (Minneapolis, MN). All data presented is as a mean value (ng/ml) of multiple samples based on the standard curve. IC50's where appropriate are generated by non-linear regression analysis.

10


The above description fully discloses the invention including preferred embodiments thereof. Modifications and improvements of the embodiments specifically disclosed herein are within the scope of the following claims. Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. Therefore the Examples herein are to be construed as merely illustrative and not a limitation of the scope of the present invention in any way. The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows.

15

-31-

What is Claimed is:

1. A compound of the formula:



wherein

R₁ is a mono- or di- substituted 4-quinolyl, 4-pyridyl, 1-imidazolyl, 1-benzimidazolyl, 4-pyrimidinyl wherein the substituent is independently selected from the group consisting of hydrogen, C₁₋₄ alkyl, halo, O-C₁₋₄ alkyl, S-C₁₋₄ alkyl, or N(R_a)₂;

R_a is hydrogen, C₁₋₆alkyl, or R_a may form a heterocyclic ring of 5 to 7 members together with the nitrogen, said ring optionally containing an additional heteroatom selected from the group consisting of oxygen, sulfur or nitrogen;

R₂ is mono- or di-substituted phenyl wherein the substituents are independently selected from the group consisting of hydrogen, halo, S(O)_mR₅, OR₆, halo substituted C₁₋₄ alkyl, C₁₋₄ alkyl, or N(R₁₂)₂;

R₄ is hydrogen, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₃₋₇ cycloalkyl, C₅₋₇ cycloalkenyl, heterocyclic, heterocyclicalkyl, aryl, aryl alkyl, heteroaryl, heteroaryl alkyl ;

R₃ is (X)_r(Q)_s(Y)_t;

X is hydrogen, -(C(R₁₀)₂)_n , -NR₁₃, -O- or S(O)_m;

r is a number having a value of 0 or 1;

m is a number having a value of 0, 1 or 2;

Q is alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclic, heterocyclicalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl;

s is a number having a value of 0 or 1;

-32-

Y is a substituent selected from the group consisting of hydrogen, C₁₋₁₀ alkyl,

halo-substituted C₁₋₁₀ alkyl, halogen, $-(C(R_{10})_2)_nOR_8$, $-(C(R_{10})_2)_nNO_2$,

$-(C(R_{10})_2)_nS(O)_mR_{11}$, $-(C(R_{10})_2)_nSR_8$, $-(C(R_{10})_2)_nS(O)_mOR_8$,

$-(C(R_{10})_2)_nS(O)_mNR_8R_9$, $-X_a-P(Z)-(X_aR_{13})_2$, $-(C(R_{10})_2)_nNR_8R_9$,

5 $-(C(R_{10})_2)_nCO_2R_8$, $-(C(R_{10})_2)_nOC(O)R_8$, $-(C(R_{10})_2)_nCN$,

$-(C(R_{10})_2)_nCONR_8R_9$, $-(C(R_{10})_2)_nC(S)NR_8R_9$, $-(C(R_{10})_2)_nNR_{10}C(O)R_8$,

$-(C(R_{10})_2)_nNR_{10}C(S)R_8$, $-(C(R_{10})_2)_nNR_{10}C(Z)NR_8R_9$,

$-(C(R_{10})_2)_nNR_{10}S(O)_mR_{11}$, $-(C(R_{10})_2)_nNR_{10}C(=NCN)-S-R_{11}$,

$-(C(R_{10})_2)_nNR_{10}C(=NCN)-NR_8R_9$, $-(C(R_{10})_2)_nNR_{10}C(O)C(O)-NR_8R_9$,

10 $-(C(R_{10})_2)_nNR_{10}C(O)C(O)-OR_{10}$, $-(C(R_{10})_2)_nC(=NR_{10})-NR_8R_9$,

$-(C(R_{10})_2)_nC(=NR_{10})-ZR_{11}$, $-(C(R_{10})_2)_nOC(Z)-NR_8R_9$,

$-(C(R_{10})_2)_nNR_{10}S(O)_mCF_3$, $-(C(R_{10})_2)_nNR_{10}C(O)OR_{10}$;

t is a number having a value of 0, 1, 2, or 3;

X_a is independently $-(C(R_{10})_2)_n$, $-NR_8$, $-O$ or $-S$;

15 Z is oxygen or sulfur;

m' is a number having a value of 1 or 2;

n is a number having a value of 0 to 10;

R₅ is hydrogen, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇ cycloalkyl, C₅₋₇

cycloalkenyl, aryl, or N(R₇)₂; provided that when m is 1 or 2 then R₅ is not

20 hydrogen.

R₆ is hydrogen, C₁₋₄ alkyl, halo substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl,

C₃₋₇ cycloalkyl, C₅₋₇ cycloalkenyl, or aryl;

R₇ is hydrogen, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, aryl, or may form a

heterocyclic ring of 5 to 7 members together with the nitrogen, said ring

25 optionally containing an additional heteroatom selected from the group

consisting of oxygen, sulfur or nitrogen; provided that when R₅ is N(R₇)₂

then m is 1 or 2;

-33-

R₈ is hydrogen, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₃₋₇ cycloalkyl, C₅₋₇ cycloalkenyl, heterocyclic, heterocyclic alkyl, aryl, aryl alkyl, heteroaryl, heteroaryl alkyl ;

5 R₉ is hydrogen, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₃₋₇ cycloalkyl, C₅₋₇ cycloalkenyl, aryl, aryl alkyl, heteroaryl, heteroaryl alkyl or R₈ and R₉ may together form a heterocyclic ring of 5 to 7 members together with the nitrogen, said ring optionally containing an additional heteroatom selected from the group consisting of oxygen, sulfur or nitrogen;

R₁₀ is hydrogen, or C₁₋₄ alkyl;

10 R₁₁ is C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₃₋₇ cycloalkyl, C₅₋₇ cycloalkenyl, aryl, aryl alkyl, heteroaryl, heteroaryl alkyl ;

R₁₂ is hydrogen, C₁₋₄ alkyl, aryl, or may form a heterocyclic ring of 5 to 7 members together with the nitrogen;

15 R₁₃ is hydrogen, C₁₋₁₀ alkyl, cycloalkyl, heterocyclic, aryl, aryl alkyl, heteroaryl, or heteroaryl alkyl;

or a pharmaceutically acceptable salt thereof.

2. The compound according to Claim 1 wherein R₁ is a mono- or di-substituted 4- pyridyl or 4-quinolyl.

20

3. The compound according to Claim 2 wherein s is 0.

4. The compound according to Claim 3 wherein r is 0.

25

5. The compound according to Claim 4 wherein Y is alkyl, -(C(R₁₀)₂)_nOR₈, -(C(R₁₀)₂)_nS(O)_mR₁₁, -(C(R₁₀)₂)_nSR₈, -(C(R₁₀)₂)_nS(O)_mOR₈, -(C(R₁₀)₂)_nS(O)_mNR₈R₉, -X_a-P(Z)-(X_aR₁₃)₂, -(C(R₁₀)₂)_nNR₈R₉, -(C(R₁₀)₂)_nC(Z)OR₈, -(C(R₁₀)₂)_nOC(Z)-R₈, -(C(R₁₀)₂)_nC(O)NR₈R₉, -(C(R₁₀)₂)_nNR₁₀C(=NCN)-NR₈R₉, or 30 -(C(R₁₀)₂)_nNR₁₀S(O)_mR₁₁.

6. The compound according to Claim 5 wherein Y is alkyl, $-(C(R_{10})_2)_nOR_8$, $(CH_2)_nS(O)_mR_6$, $(CH_2)_nCO_2R_8$, $-(C(R_{10})_2)_nNR_{10}C(=NCN)-NR_8R_9$, $-(C(R_{10})_2)_nNR_8R_9$, $-X_a-P(Z)-(X_aR_{13})_2$; and n is 0 to 4.
- 5 7. The compound according to Claim 2 wherein s is 1.
8. The compound according to Claim 7 wherein Q is aryl or heteroaryl.
- 10 9. The compound according to Claim 8 wherein Y is alkyl, $-(C(R_{10})_2)_nOR_8$, $-(C(R_{10})_2)_nS(O)_mR_{11}$, $-(C(R_{10})_2)_nSR_8$, $-(C(R_{10})_2)_nS(O)_mOR_8$, $-(C(R_{10})_2)_nS(O)_mNR_8R_9$, $-X_a-P(Z)-(X_aR_{13})_2$, $-(C(R_{10})_2)_nNR_8R_9$, $-(C(R_{10})_2)_nC(Z)OR_8$, $-(C(R_{10})_2)_nOC(Z)-R_8$, $-(C(R_{10})_2)_nC(O)NR_8R_9$, $-(C(R_{10})_2)_nNR_{10}C(=NCN)-NR_8R_9$, or
- 15 $-(C(R_{10})_2)_nNR_{10}S(O)_mR_{11}$.
10. The compound according to Claim 8 wherein r is 0, or r is 1 and X is $-(C(R_{10})_2)_n$.
- 20 11. The compound according to Claim 8 wherein R_4 is hydrogen or alkyl.
12. The compound according to Claim 2 wherein R_2 is a mono-substituted phenyl wherein the substituents are independently selected from the
- 25 group consisting of hydrogen, halo, $S(O)_mR_6$, OR_9 , or C_{1-4} alkyl.
13. The compound according to Claim 2 wherein R_1 is 4-pyridyl optionally substituted in the 2-position with a C_{1-4} alkyl.
- 30 14. The compound according to Claim 1 wherein R_2 is a mono-substituted phenyl wherein the substituents are independently selected from the group consisting of hydrogen, halo, $S(O)_mR_6$, OR_9 , or C_{1-4} alkyl; r is 0, s is 1, Q is aryl, Y is hydrogen, alkyl, $-(C(R_{10})_2)_nOR_8$, $-(C(R_{10})_2)_nS(O)_mR_{11}$, $-(C(R_{10})_2)_nSR_8$, $-(C(R_{10})_2)_nS(O)_mOR_8$, $-(C(R_{10})_2)_nS(O)_mNR_8R_9$,
- 35 $-X_a-P(Z)-(X_aR_{13})_2$, $-(C(R_{10})_2)_nNR_8R_9$, $-(C(R_{10})_2)_nCO_2R_8$, $-(C(R_{10})_2)_nOC(O)-R_8$, $-(C(R_{10})_2)_nCONR_8R_9$, $-(C(R_{10})_2)_nNR_{10}C(=NCN)-NR_8R_9$, or $-(C(R_{10})_2)_nNR_{10}S(O)_mR_{11}$, R_4 is hydrogen or methyl, R_8 is hydrogen, C_{1-4}

-35-

alkyl, or may optionally cyclize with R₉ to form a 5 membered heterocyclic ring together with the nitrogen to which they are attached.

15. The compound according to Claim 1 which is

- 5 1-(4-pyridyl)-2-(4-fluorophenyl)-4-phenylimidazole;
1-(4-pyridyl)-2-(4-fluorophenyl)-4-(4-hydroxyphenyl) imidazole;
1-(4-pyridyl)-2-(4-fluorophenyl)-4-(4-thiomethylphenyl) imidazole;
1-(4-pyridyl)-2-(4-fluorophenyl)-4-(4-methylsulfinylphenyl) imidazole;
1-(4-pyridyl)-2-(4-fluorophenyl)-4-methylimidazole;
10 1-(2-methylpyrid-4-yl)-2-(4-fluorophenyl)-4-(4-thiomethylphenyl)imidazole; or
1-(2-methylpyrid-4-yl)-2-(4-fluorophenyl)-4-(4-methylsulfinylphenyl)imidazole.

16. A pharmaceutical or veterinary composition comprising an effective amount of a compound according to Claim 1 and a pharmaceutically or
15 veterinary acceptable carrier or diluent.

17. The pharmaceutical or veterinary composition comprising an effective amount of a compound according to Claim 15 and a pharmaceutically or
20 veterinary acceptable carrier or diluent.

18. A method of treating a cytokine mediated disease in a human in need of such treatment, which comprises administering to said human an effective cytokine interfering amount of a compound of Formula (I), according to Claim 1.

25 19. The method according to Claim 18 wherein the cytokine inhibited is IL-1.

20. The method according to Claim 18 wherein the cytokine inhibited is TNF.

30 21. The method according to Claim 18 wherein the cytokine inhibited is IL-8.

22. The method according to Claim 18 wherein the cytokine mediated
35 disease is septic shock, endotoxic shock, gram negative sepsis, or toxic shock syndrome.

-36-

23. The method according to Claim 18 wherein the cytokine mediated disease is bone resorption diseases, graft versus host reaction, atherosclerosis, arthritis, osteoarthritis, rheumatoid arthritis, gout, psoriasis, or topical inflammatory disease states.

5

24. The method according to Claim 18 wherein the cytokine mediated disease is adult respiratory distress syndrome, asthma, or chronic pulmonary inflammatory disease.

10

25. The method according to Claim 18 wherein the cytokine mediated disease is Crohn's disease, ulcerative colitis, or inflammatory bowel disease.

26. The method according to Claim 18 wherein the cytokine mediated disease is cardiac and renal reperfusion injury, thrombosis or glomerulonephritis.

15

27. The method according to Claim 18 wherein the cytokine mediated disease is cachexia.

28. The method according to Claim 18 wherein the compound of Formula (I) is

20

1-(4-pyridyl)-2-(4-fluorophenyl)-4-phenylimidazole;
1-(4-pyridyl)-2-(4-fluorophenyl)-4-(4-hydroxyphenyl)imidazole;
1-(4-pyridyl)-2-(4-fluorophenyl)-4-(4-thiomethylphenyl)imidazole;
1-(4-pyridyl)-2-(4-fluorophenyl)-4-(4-methylsulfinylphenyl)imidazole;
25 1-(4-pyridyl)-2-(4-fluorophenyl)-4-methylimidazole;
1-(2-methylpyrid-4-yl)-2-(4-fluorophenyl)-4-(4-thiomethylphenyl)imidazole; or
1-(2-methylpyrid-4-yl)-2-(4-fluorophenyl)-4-(4-methylsulfinylphenyl)imidazole.

25

29. A method of treating a cytokine mediated disease in an animal, excluding humans, in need of such treatment, which comprises administering to said human an effective cytokine interfering amount of a compound of Formula (I), according to Claim 1.

30

30. The method according to Claim 29 wherein the cytokine mediated disease is a viral infection.

35

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US93/00675**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(5) :C07D 401/04; A61K 31/44

US CL :546/278,25,22;514/341.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : NONE

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS on line structural search

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US,A, 4,058,614 (Baldwin) 15 November 1977 see whole document.	1-17
A	US,A, 3,850,944 (Tanaka et al.) 26 November 1974 see whole document.	1-17, 24

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	"T" Inter document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be part of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Z" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 13 APRIL 1993	Date of mailing of the international search report 03 JUN 1993
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. NOT APPLICABLE	Authorized officer JANE T. FAN Telephone No. (703) 308-1235